Talphera (TLPH) Stock Price, News & Analysis

Company Overview

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $1.04 to $1.24
• 50-Day Range: $0.41 to $1.32
• 52-Week Range: $0.38 to $1.45
• Volume: 425,931 shs
• Average Volume: 424,863 shs
• Market Capitalization: $48.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Talphera Stock Analysis - MarketRank™

Talphera scored higher than 49% of companies evaluated by MarketBeat, and ranked 624th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Talphera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Talphera has a consensus price target of $5.00, representing about 367.3% upside from its current price of $1.07.

Amount of Analyst Coverage

Talphera has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Talphera are expected to decrease in the coming year, from ($0.64) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Talphera is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Talphera is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Talphera has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.47% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Talphera has recently decreased by 27.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Talphera does not currently pay a dividend.

Dividend Growth

Talphera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.47% of the float of Talphera has been sold short.

Short Interest Ratio / Days to Cover

Talphera has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Talphera has recently decreased by 27.35%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.30

News Sentiment

Talphera has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Talphera this week, compared to 1 article on an average week.

Search Interest

Only 17 people have searched for TLPH on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.

MarketBeat Follows

1 people have added Talphera to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Talphera insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.70% of the stock of Talphera is held by insiders.

Percentage Held by Institutions

Only 37.67% of the stock of Talphera is held by institutions.

TLPH Stock Analysis - Frequently Asked Questions

How have TLPH shares performed this year?

Talphera's stock was trading at $0.5241 at the beginning of the year. Since then, TLPH stock has increased by 104.2% and is now trading at $1.07.

How were Talphera's earnings last quarter?

Talphera, Inc. (NASDAQ:TLPH) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02.
Read the conference call transcript.

How do I buy shares of Talphera?

Shares of TLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Talphera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Talphera investors own include Clearside Biomedical (CLSD), Terran Orbital (LLAP), Adverum Biotechnologies (ADVM), Aptinyx (APTX), Exela Technologies (XELA) and Xeris Biopharma (XERS).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLPH
• Previous Symbol: NASDAQ:TLPH
• CIK: 1427925
• Web: talphera.com
• Phone: 650-216-3500
• Fax: 650-216-6500
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Talphera: $5.00
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +367.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13 million
• Net Margins: N/A
• Pretax Margin: -42,140.74%
• Return on Equity: -152.38%
• Return on Assets: -64.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $650 thousand
• Price / Sales: 75.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 45,590,000
• Free Float: 42,988,000
• Market Cap: $48.78 million
• Optionable: Optionable
• Beta: 0.03